Clinical Trial Search

Primary: Number of Participants With Treatment Emergent Adverse Events (TEAEs) Including Adverse Events of Special Interest (AESI) and Serious Adverse Events (SAEs) During…

Primary: Insomnia Severity Index Change — 8.54; 11.88 score on a scale — p=<0.01

Primary: Tolerance (Time): Percent of Intended Treatment Hours That Patient Continues With the Delivery of Bright Light — 59; 61 percentage of intended treatment hours

Primary: Physical Activity Energy Expenditure (kJ/Day or kcal/Day) — 1229; 1096; 1275; 1142 kcal/d

Primary: Change in 24-hr Proteinuria With Dapagliflozin for Six Weeks Relative to Placebo in Patients With Non-diabetic Kidney Disease and Proteinuria 500 mg/Day on Stable…

Primary: Number of Participants With Adverse Events (AEs) — 216; 120 Participants

Primary: Tibial Blood Perfusion — 0.54; -1.47; 0.43; 2.08 μM (concentration)

Primary: Number of Participants With Solicited Local and Systemic Reactogenicity Adverse Reaction (ARs)-First Vaccination — 0; 0; 0; 1 Participants

Primary: Part A: Number of Participants With Solicited Adverse Events- Vaccination 1 — 17; 20; 24; 0 Participants

Primary: Difference in Time to Onset of Calf Pain (Claudication Onset Time) Pre-intervention to Post-intervention — 396; 140 seconds — p=0.028

Primary: Short Term Change in Weight — 1.7; -0.76 Kilogram

Primary: Session Attendance — 6.77; 5.56 sessions

Primary: Mobility: Figure-of-eight Walking Test (Figure-8 Walk Test) — 10.57; 9.58; 11.00 seconds

Primary: Percentage of Participants Achieving Palmoplantar Investigator's Global Assessment (ppIGA) of "Clear" or "Almost Clear" (0 or 1) With at Least a 2-point Reduction From…

Primary: Progression Free Survival (PFS) as Assessed by the Investigator According to Response Evaluation Criteria In Solid Tumors v1.1 (RECIST v1.1) — 6.14; 4.40 Months — p=0.0177